-+ 0.00%
-+ 0.00%
-+ 0.00%

Lumos Pharma Presents Updated Phase 2 OraGrowtH Data Demonstrating Sustained Growth On Oral LUM-201 To 24 Months In PGHD And Correlation Of Growth To LUM-201's Unique Pulsatile Mechanism Of Action At ESPE 2024

Benzinga·11/21/2024 14:15:05
Listen to the news

Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that new analyses of data from its Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials were presented orally at the 62nd Annual European Society for Paediatric Endocrinology Meeting, or ESPE 2024, held November 16-18, 2024 in Liverpool, UK.